Related Experiment Videos
PPARs: therapeutic targets for metabolic disease
Joel P Berger1, Taro E Akiyama, Peter T Meinke
1Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA. joel_berger@merck.com
Trends in Pharmacological Sciences
|April 30, 2005
Summary
Peroxisome-proliferator-activated receptors (PPARs) are key nuclear receptors regulating metabolism and treating diseases like diabetes. New PPAR ligands show promise for broader efficacy and better tolerability in metabolic syndrome treatments.
Area of Science:
- Molecular biology
- Endocrinology
- Metabolic research
Background:
- Peroxisome-proliferator-activated receptors (PPARs) are nuclear receptors that regulate gene expression.
- PPARs act as lipid sensors, influencing key metabolic processes.
- Existing PPAR-targeting drugs treat type 2 diabetes and atherosclerosis.
Purpose of the Study:
- To review the role of PPAR subtypes (PPAR-gamma, PPAR-alpha, PPAR-delta) in metabolic regulation.
- To highlight the therapeutic potential of PPAR modulation for metabolic syndrome, including obesity.
- To discuss the development of novel PPAR ligands with improved properties.
Main Methods:
- Literature review of PPAR research over the past decade.
- Analysis of PPAR's function as a lipid sensor and regulator of gene expression.
- Examination of current and emerging therapeutic applications of PPAR ligands.
Main Results:
- PPARs are crucial in coordinating metabolic events through gene regulation.
- PPARs are validated drug targets for type 2 diabetes and atherosclerosis.
- Modulating PPAR activity may offer new treatments for obesity and other metabolic disorders.
Conclusions:
- PPARs are central to metabolic control and represent significant therapeutic targets.
- Ongoing development of novel PPAR ligands aims for enhanced efficacy and tolerability.
- Targeting PPARs holds promise for managing widespread metabolic diseases.